Video & Webinars

An interim analysis of a large phase III study suggests that the combination of ibrutinib and bendamustine/rituximab (BR) improves outcomes for patients…

Dr A. Erdem Canda Chairs a Discussion on the Trends and Developments in the Field of Endourology

An Interview with Dr. Abolfazl Hosseni at the 11th National Endourology Congress, Discussing the Developing Treatment in Bladder Cancer

An Interview with Dr. Abhay Rane at the 11th National Endourology Congress, Discussing the Key Points of the Upcoming World Congess of Endourology

An Interview with Dr. John W. Davis at the 11th National Endourology Congress, Discussing the Key Points from the Congress

An Interview with Dr. Kevin C. Zorn at the 11th National Endourology Congress, Discussing Developments within the Field

Findings from a phase I/II study suggest that nivolumab is safe and effective in advanced liver cancer. Based on the results of the phase I part of the…

A phase II study identified the first genomic marker – mismatch repair (MMR) deficiency – to predict response to the anti-PD-1 antibody pembrolizumab…